Galectin-3 and HBME-1 improve the accuracy of core biopsy in indeterminate thyroid nodules

详细信息    查看全文

• 作者：Pierpaolo Trimboli ; Leo Guidobaldi ; Stefano Amendola ; Naim Nasrollah…
• 关键词：Thyroid ; Nodule ; Core needle biopsy (CNB) ; Galectin ; 3
• 刊名：Endocrine
• 出版年：2016
• 出版时间：April 2016
• 年：2016
• 卷：52
• 期：1
• 页码：39-45
• 全文大小：597 KB
• 参考文献：1.H. Gharib, E. Papini, R. Paschke, D.S. Duick, R. Valcavi, L. Hegedüs, P. Vitti, AACE/AME/ETA Task Force on Thyroid Nodules, American association of clinical endocrinologists, associazione medici endocrinologi, and europeanthyroid association medical guidelines for clinical practice for the diagnosis and management of thyroid nodules. Endocr. Pract. 1, 1–43 (2010)CrossRef
  2.American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, D.S. Cooper, G.M. Doherty, B.R. Haugen, R.T. Kloos, S.L. Lee, S.J. Mandel, E.L. Mazzaferri, B. McIver, F. Pacini, M. Schlumberger, S.I. Sherman, D.L. Steward, R.M. Tuttle, Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19, 1167–1214 (2009)CrossRef
  3.P. Trimboli, G. Treglia, L. Guidobaldi, E. Saggiorato, G. Nigri, A. Crescenzi, F. Romanelli, F. Orlandi, S. Valabrega, R. Sadeghi, L. Giovanella, Clinical characteristics as predictors of malignancy in patients with indeterminate thyroid cytology: a meta-analysis. Endocrine 46, 52–59 (2014)CrossRef PubMed
  4.P. Trimboli, E. Condorelli, A. Catania, S. Sorrenti, Clinical and ultrasound parameters in the approach to thyroid nodules cytologically classified as indeterminate neoplasm. Diagn. Cytopathol. 37, 783–785 (2009)CrossRef PubMed
  5.E.K. Alexander, G.C. Kennedy, Z.W. Baloch, E.S. Cibas, D. Chudova, J. Diggans, L. Friedman, R.T. Kloos, V.A. LiVolsi, S.J. Mandel, S.S. Raab, J. Rosai, D.L. Steward, P.S. Walsh, J.I. Wilde, M.A. Zeiger, R.B. Lanman, B.R. Haugen, Preoperative diagnosis of benign thyroid nodules with indeterminate cytology. N. Engl. J. Med. 367, 705–715 (2012)CrossRef PubMed
  6.E. Saggiorato, Pompa R. De, M. Volante, S. Cappia, F. Arecco, A.P. Dei Tos, F. Orlandi, M. Papotti, Characterization of thyroid ‘follicular neoplasms’ in fine-needle aspiration cytological specimens using a panel of immunohistochemical markers: a proposal for clinical application. Endocr. Relat. Cancer 12, 305–317 (2005)CrossRef PubMed
  7.A. Bartolazzi, F. Orlandi, E. Saggiorato, M. Volante, F. Arecco, R. Rossetto, N. Palestini, E. Ghigo, M. Papotti, G. Bussolati, M.P. Martegani, F. Pantellini, A. Carpi, M.R. Giovagnoli, S. Monti, V. Toscano, S. Sciacchitano, G.M. Pennelli, C. Mian, M.R. Pelizzo, M. Rugge, G. Troncone, L. Palombini, G. Chiappetta, G. Botti, A. Vecchione, R. Bellocco, Italian Thyroid Cancer Study Group (ITCSG), Galectin-3-expression analysis in the surgical selection of follicular thyroid nodules with indeterminate fine-needle aspiration cytology: a prospective multicentre study. Lancet. Oncol. 9, 543–549 (2008)CrossRef PubMed
  8.G. Fadda, E.D. Rossi, M. Raffaelli, A. Pontecorvi, S. Sioletic, F. Morassi, C.P. Lombardi, G.F. Zannoni, G. Rindi, Follicular thyroid neoplasms can be classified as low- and high-risk according to HBME-1 and Galectin-3 expression on liquid-based fine-needle cytology. Eur. J. Endocrinol. 165, 447–453 (2011)CrossRef PubMed
  9.P. Trimboli, A. Crescenzi, Thyroid core needle biopsy: taking stoke of the situation. Endocrine 48, 779–785 (2015)CrossRef PubMed
  10.K.T. Park, S.H. Ahn, J.H. Mo, Y.J. Park, J. Park, S.I. Choi, S.Y. Park, Role of core needle biopsy and ultrasonographic finding in management of indeterminate thyroid nodules. Head Neck 33, 160–165 (2011)CrossRef PubMed
  11.N. Nasrollah, P. Trimboli, L. Guidobaldi, D.D. Cicciarella Modica, C. Ventura, G. Ramacciato, S. Taccogna, F. Romanelli, S. Valabrega, A. Crescenzi, Thin core biopsy should help to discriminate thyroid nodules cytologically classified as indeterminate. A new sampling technique. Endocrine 43, 659–665 (2013)CrossRef PubMed
  12.N. Nasrollah, P. Trimboli, F. Rossi, S. Amendola, L. Guidobaldi, C. Ventura, R. Maglio, G. Nigri, F. Romanelli, S. Valabrega, A. Crescenzi, Patient’s comfort with and tolerability of thyroid core needle biopsy. Endocrine 45, 79–83 (2014)CrossRef PubMed
  13.D.G. Na, J.H. Kim, J.Y. Sung, J.H. Baek, K.C. Jung, H. Lee, H. Yoo, Core-needle biopsy is more useful than repeat fine-needle aspiration in thyroid nodules read as nondiagnostic or atypia of undetermined significance by the bethesda system for reporting thyroid cytopathology. Thyroid 22, 468–475 (2012)CrossRef PubMed
  14.Y.J. Choi, J.H. Baek, E.J. Ha, H.K. Lim, J.H. Lee, J.K. Kim, D.E. Song, Y. Shong, S.J. Hong, Different risk of malignancy and management recommendations in subcategories of thyroid nodules with atypia of undetermined significance (AUS) or follicular lesion of undetermined significance (FLUS): the role of US-guided core-needle biopsy (CNB). Thyroid 24, 494–501 (2014)CrossRef PubMed
  15.G. Fadda, F. Basolo, A. Bondi, G. Bussolati, A. Crescenzi, O. Nappi, F. Nardi, M. Papotti, G. Taddei, L. Palombini, Cytological classification of thyroid nodules. Proposal of the SIAPEC-IAP Italian Consensus Working Group. Pathologica 102, 405–408 (2010)PubMed
  16.R. De Lellis, R. Lloyd, P. Heitz, C. Eng, Pathology and genetics of tumour of endocrine organs, in World Health Organization classification of tumours, ed. by P. Kleihues, L. Sobin (IARC, Lyon, 2004), pp. 49–133
  17.P. Trimboli, N. Nasrollah, L. Guidobaldi, S. Taccogna, D.D. Cicciarella Modica, S. Amendola, F. Romanelli, A. Lenzi, G. Nigri, M. Centanni, L. Giovanella, S. Valabrega, A. Crescenzi, The use of core needle biopsy as first-line in diagnosis of thyroid nodules reduces false negative and inconclusive data reported by fine-needle aspiration. World J. Surg. Oncol. 12, 61 (2014)CrossRef PubMed PubMedCentral
  18.M.R. Nasr, S. Mukhopadhyay, S. Zhang, A.L. Katzenstein, Immunohistochemical markers in diagnosis of papillary thyroid carcinoma: utility of HBME 1 combined with CK-19 immunostaining. Mod. Pathol. 19, 1631–1637 (2006)CrossRef PubMed
  19.M. Papotti, J. Rodriguez, R. De Pompa, A. Bartolazzi, J. Rosai, Galectin-3 and HBME-1 expression in well-differentiated thyroid tumors with follicular architecture of uncertain malignant potential. Mod. Pathol. 18, 541–546 (2005)CrossRef PubMed
  20.A. Bartolazzi, A. Gasbarri, M. Papotti, G. Bussolati, T. Lucante, A. Khan, H. Inohara, F. Marandino, F. Orlandi, F. Nardi, A. Vecchione, R. Tecce, O. Larsson, Application of an immunodiagnostic method for improving preoperative diagnosis of nodular thyroid lesions. Lancet 357, 1644–1650 (2001)CrossRef PubMed
  21.C.G. Chiu, S.S. Strugnell, O.L. Griffith, S.J. Jones, A.M. Gown, B. Walker, I.R. Nabi, S.M. Wiseman, Diagnostic utility of galectin-3 in thyroid cancer. Am. J. Pathol. 176, 2067–2081 (2010)CrossRef PubMed PubMedCentral
  22.O.L. Griffith, C.G. Chiu, A.M. Gown, S.J.M. Jones, S.M. Wiseman, Biomarker panel diagnosis of thyroid cancer: a critical review. Expert Rev. Anticancer Ther. 8, 1399–1413 (2008)CrossRef PubMed
  23.A.A. Renshaw, N. Pinnar, Comparison of thyroid fine-needle aspiration and core needle biopsy. Am. J. Clin. Pathol. 128, 370–374 (2007)CrossRef PubMed
  24.D. Capper, M. Preusser, A. Habel, F. Sahm, U. Ackermann, G. Schindler, S. Pusch, G. Mechtersheimer, H. Zentgraf, A. von Deimling, Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody. Acta Neuropathol. 122, 11–19 (2011)CrossRef PubMed
  25.A. Crescenzi, L. Guidobaldi, N. Nasrollah, S. Taccogna, D.D. Cicciarella Modica, L. Turrini, G. Nigri, F. Romanelli, S. Valabrega, L. Giovanella, A. Onetti Muda, P. Trimboli, Immunohistochemistry for BRAF(V600E) antibody VE1 performed in core needle biopsy samples identifies mutated papillary thyroid cancers. Horm. Metab. Res. 46, 370–374 (2014)CrossRef PubMed
  26.T.J. Sebo, What are the keys to successful thyroid FNA interpretation? Clin. Endocrinol. 77, 13–17 (2012)CrossRef
  27.P. Trimboli, M. Bongiovanni, F. Rossi, L. Guidobaldi, A. Crescenzi, L. Ceriani, G. Nigri, S. Valabrega, F. Romanelli, L. Giovanella, Differentiated thyroid cancer patients with a previous indeterminate (Thy 3) cytology have a better prognosis than those with suspicious or malignant FNAC reports. Endocrine 49, 191–195 (2015)CrossRef PubMed
  28.T. Rago, M. Scutari, F. Latrofa, V. Loiacono, P. Piaggi, I. Marchetti, R. Romani, F. Basolo, P. Miccoli, M. Tonacchera, P. Vitti, The large majority of 1520 patients with indeterminate thyroid nodule at cytology have a favorable outcome, and a clinical risk score has a high negative predictive value for a more cumbersome cancer disease. J. Clin. Endocrinol. Metab. 99, 3700–3707 (2014)CrossRef PubMed
  29.F. Nardi, F. Basolo, A. Crescenzi, G. Fadda, A. Frasoldati, F. Orlandi, L. Palombini, E. Papini, M. Zini, A. Pontecorvi, P. Vitti, Italian consensus for the classification and reporting of thyroid cytology. J. Endocrinol. Invest. 37, 593–599 (2014)CrossRef PubMed
  30.E.S. Cibas, S.Z. Ali, The Bethesda system for reporting thyroid cytopathology. Thyroid 19, 1159–1165 (2009)CrossRef PubMed
  31.A. Carpi, A.G. Naccarato, G. Iervasi, A. Nicolini, G. Bevilacqua, P. Viacava, P. Collecchi, L. Lavra, C. Marchetti, S. Sciacchitano, A. Bartolazzi, Large needle aspiration biopsy and galectin-3 determination in selected thyroid nodules with indeterminate FNA-cytology. Br. J. Cancer 95, 204–209 (2006)CrossRef PubMed PubMedCentral
  32.V.A. LiVolsi, S.L. Asa, The demise of follicular carcinoma of the thyroid gland. Thyroid 4, 233–236 (1994)CrossRef PubMed
  
• 作者单位：Pierpaolo Trimboli (1)
  Leo Guidobaldi (2)
  Stefano Amendola (1)
  Naim Nasrollah (3)
  Francesco Romanelli (4)
  Daniela Attanasio (5)
  Giovanni Ramacciato (6)
  Enrico Saggiorato (7)
  Stefano Valabrega (6)
  Anna Crescenzi (8)
  
  1. Section of Endocrinology and Diabetology, Ospedale Israelitico, Via Fulda, 14, 00148, Rome, Italy
  2. Section of Pathology, Ospedale Israelitico, Rome, Italy
  3. Section of Surgery, Ospedale Israelitico, Rome, Italy
  4. Department of Experimental Medicine, Sapienza University, Rome, Italy
  5. Endocrinology, Azienda Sanitaria Locale, Viterbo, Italy
  6. Department of Surgical and Medical Science, Sapienza University, Ospedale S. Andrea, Rome, Italy
  7. Service d’Endocrinologie, Pôle de Médecine, Centre Hospitalier des Escartons, Briançon, France
  8. Section of Pathology, University Hospital Campus Bio Medico, Rome, Italy
  
• 刊物主题：Endocrinology; Diabetes; Internal Medicine; Science, general;
• 出版者：Springer US
• ISSN：1559-0100

文摘

Core needle biopsy (CNB) has been recently described as an accurate second-line test in thyroid inconclusive cytology (FNA). Here we retrospectively investigated the potential improvement given by Galectin-3, Cytokeratin-19, and HBME-1 on the accuracy of CNB in thyroid nodules with prior indeterminate FNA report. The study included 74 nodules. At CNB diagnosis, 15 were cancers, 40 were benign, and 19 had uncertain/non-diagnostic CNB report. The above immunohistochemical (IHC) panel was analyzed in all cases. After surgery, 19 malignant and 55 benign lesions were found. All 15 cancers and all 40 benign nodules diagnosed at CNB were confirmed at final histology. Regarding the uncertain CNB group, 4 (21 %) were malignant and 15 (79 %) benign. When we considered all the series, the most accurate IHC combination was Galectin-3 plus HBME-1, while HBME-1 was the most sensitive marker in those nodules with uncertain CNB report. The combination of CNB plus IHC could indentify 19/19 cancers and 53/55 benign lesions. Sensitivity and specificity of CNB increased from 79 to 100 % and from 73 to 96 %, respectively, by adding IHC. CNB can diagnose the majority of thyroid nodules with previous indeterminate FNA cytology, while the accuracy of CNB is increased by adding Galectin-3, Cytokeratin-19, and HBME-1 panel. We suggest to adopt CNB as a second-line approach to indeterminate thyroid FNA, and apply IHC in those lesions with uncertain/non-diagnostic CNB report. This approach should improve the pre-surgical diagnosis of patients. These results should be confirmed in larger prospective series.